Last reviewed 2026-05-20 · How we verify

Glucurone (GLUCUROLACTONE)

Phase 2 active Small molecule ✓ Verified May 2026

Glucurone (generic name: GLUCUROLACTONE) is a glucurolactone drug. It is currently in Phase 2 development.

Glucurone works by interacting with a specific biological target, although its exact mechanism of action is currently unknown.

Glucurone is a small molecule with the synonyms D-GLUCURONOLACTONE, D-GLUCURONOLACTONE, GLUCUROLACTONA, GLUCUROLACTONE, GLUCURONOLACTONE, and GURONSAN.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	GLUCUROLACTONE
Drug class	glucurolactone
Modality	Small molecule
Therapeutic area	Urology
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and Glucurone is a key that fits into one of those locks. When it binds to the lock, it can either block or enhance the activity of the cell, depending on the specific target. However, without more information, it's difficult to say exactly how Glucurone works or what it does.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Glucurone CI brief — competitive landscape report
Glucurone updates RSS · CI watch RSS

Frequently asked questions about Glucurone

What is Glucurone?

Glucurone (GLUCUROLACTONE) is a glucurolactone drug.

How does Glucurone work?

Glucurone works by interacting with a specific biological target, although its exact mechanism of action is currently unknown.

What is the generic name of Glucurone?

GLUCUROLACTONE is the generic (nonproprietary) name of Glucurone.

What drug class is Glucurone in?

Glucurone belongs to the glucurolactone class. See all glucurolactone drugs at /class/glucurolactone.

What development phase is Glucurone in?

Glucurone is in Phase 2.

Drug class: All glucurolactone drugs
Therapeutic area: All drugs in Urology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing